Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00531284 · BASELINE

Baseline characteristics

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma · Source last updated 2017-08-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      3
    2. group Id
      BG001
      value
      4
    3. group Id
      BG002
      value
      7
    4. group Id
      BG003
      value
      65
    5. group Id
      BG004
      value
      6
    6. group Id
      BG005
      value
      7
    7. group Id
      BG006
      value
      6
    8. group Id
      BG007
      value
      10
    9. group Id
      BG008
      value
      11
    10. group Id
      BG009
      value
      4
    11. group Id
      BG010
      value
      3
    12. group Id
      BG011
      value
      24
    units
    Participants
groups
  1. description
    Participants with solid tumors (ST) received carfilzomib (CFZ) 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG000
    title
    P1B ST: CFZ 20 mg/m² Bolus
  2. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG001
    title
    P1B ST: CFZ 20/27 mg/m² Bolus
  3. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG002
    title
    P1B ST: CFZ 20/36 mg/m² Bolus
  4. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG003
    title
    P2 ST: CFZ 20/36 mg/m² Bolus
  5. description
    Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG004
    title
    P1B ST: CFZ 36 mg/m²
  6. description
    Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG005
    title
    P1B ST: CFZ 45 mg/m²
  7. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG006
    title
    P1B ST: CFZ 20/45 mg/m²
  8. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG007
    title
    P1B ST: CFZ 20/56 mg/m²
  9. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG008
    title
    P1B ST: CFZ 20/70 mg/m²
  10. description
    Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG009
    title
    P1B MM: CFZ 20/36 mg/m²
  11. description
    Participants with multiple myeloma (MM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG010
    title
    P1B MM: CFZ 20/45 mg/m²
  12. description
    Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG011
    title
    P1b MM: CFZ 20/56 mg/m²
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          14.74
          value
          47.3
        2. group Id
          BG001
          spread
          8.81
          value
          60.8
        3. group Id
          BG002
          spread
          11.72
          value
          60.0
        4. group Id
          BG003
          spread
          9.97
          value
          62.0
        5. comment
          Not applicable for infusion arms
          group Id
          BG004
          spread
          NA
          value
          NA
        6. comment
          Not applicable for infusion arms
          group Id
          BG005
          spread
          NA
          value
          NA
        7. comment
          Not applicable for infusion arms
          group Id
          BG006
          spread
          NA
          value
          NA
        8. comment
          Not applicable for infusion arms
          group Id
          BG007
          spread
          NA
          value
          NA
        9. comment
          Not applicable for infusion arms
          group Id
          BG008
          spread
          NA
          value
          NA
        10. comment
          Not applicable for infusion arms
          group Id
          BG009
          spread
          NA
          value
          NA
        11. comment
          Not applicable for infusion arms
          group Id
          BG010
          spread
          NA
          value
          NA
        12. comment
          Not applicable for infusion arms
          group Id
          BG011
          spread
          NA
          value
          NA
      title
      Bolus Groups
    2. categories
      1. measurements
        1. comment
          Not applicable for bolus arms
          group Id
          BG000
          spread
          NA
          value
          NA
        2. comment
          Not applicable for bolus arms
          group Id
          BG001
          spread
          NA
          value
          NA
        3. comment
          Not applicable for bolus arms
          group Id
          BG002
          spread
          NA
          value
          NA
        4. comment
          Not applicable for bolus arms
          group Id
          BG003
          spread
          NA
          value
          NA
        5. group Id
          BG004
          spread
          5.18
          value
          60.0
        6. group Id
          BG005
          spread
          11.10
          value
          69.9
        7. group Id
          BG006
          spread
          10.38
          value
          61.2
        8. group Id
          BG007
          spread
          7.40
          value
          61.4
        9. group Id
          BG008
          spread
          11.58
          value
          61.6
        10. group Id
          BG009
          spread
          3.77
          value
          63.3
        11. group Id
          BG010
          spread
          5.57
          value
          72.0
        12. group Id
          BG011
          spread
          9.88
          value
          62.7
      title
      30-minute Infusion Groups
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          1
        3. group Id
          BG002
          value
          4
        4. group Id
          BG003
          value
          38
        5. group Id
          BG004
          value
          0
        6. group Id
          BG005
          value
          4
        7. group Id
          BG006
          value
          3
        8. group Id
          BG007
          value
          5
        9. group Id
          BG008
          value
          4
        10. group Id
          BG009
          value
          2
        11. group Id
          BG010
          value
          1
        12. group Id
          BG011
          value
          7
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          3
        4. group Id
          BG003
          value
          27
        5. group Id
          BG004
          value
          6
        6. group Id
          BG005
          value
          3
        7. group Id
          BG006
          value
          3
        8. group Id
          BG007
          value
          5
        9. group Id
          BG008
          value
          7
        10. group Id
          BG009
          value
          2
        11. group Id
          BG010
          value
          2
        12. group Id
          BG011
          value
          17
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          4
        4. group Id
          BG003
          value
          27
        5. group Id
          BG004
          value
          2
        6. group Id
          BG005
          value
          1
        7. group Id
          BG006
          value
          0
        8. group Id
          BG007
          value
          2
        9. group Id
          BG008
          value
          4
        10. group Id
          BG009
          value
          4
        11. group Id
          BG010
          value
          0
        12. group Id
          BG011
          value
          8
      title
      0
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          1
        3. group Id
          BG002
          value
          3
        4. group Id
          BG003
          value
          35
        5. group Id
          BG004
          value
          4
        6. group Id
          BG005
          value
          4
        7. group Id
          BG006
          value
          6
        8. group Id
          BG007
          value
          7
        9. group Id
          BG008
          value
          7
        10. group Id
          BG009
          value
          0
        11. group Id
          BG010
          value
          2
        12. group Id
          BG011
          value
          15
      title
      1
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        4. group Id
          BG003
          value
          0
        5. group Id
          BG004
          value
          0
        6. group Id
          BG005
          value
          2
        7. group Id
          BG006
          value
          0
        8. group Id
          BG007
          value
          1
        9. group Id
          BG008
          value
          0
        10. group Id
          BG009
          value
          0
        11. group Id
          BG010
          value
          1
        12. group Id
          BG011
          value
          1
      title
      2
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        4. group Id
          BG003
          value
          3
        5. group Id
          BG004
          value
          0
        6. group Id
          BG005
          value
          0
        7. group Id
          BG006
          value
          0
        8. group Id
          BG007
          value
          0
        9. group Id
          BG008
          value
          0
        10. group Id
          BG009
          value
          0
        11. group Id
          BG010
          value
          0
        12. group Id
          BG011
          value
          0
      title
      Missing
    description
    Scale used to assess how a patient's disease is progressing, how the disease affects the daily living abilities of the patient: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self care, confined to a bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.
    param Type
    NUMBER
    title
    Eastern Cooperative Oncology Group (ECOG) Performance Status
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      3
    2. group Id
      BG001
      value
      4
    3. group Id
      BG002
      value
      7
    4. group Id
      BG003
      value
      65
    5. group Id
      BG004
      value
      6
    6. group Id
      BG005
      value
      7
    7. group Id
      BG006
      value
      6
    8. group Id
      BG007
      value
      10
    9. group Id
      BG008
      value
      11
    10. group Id
      BG009
      value
      4
    11. group Id
      BG010
      value
      3
    12. group Id
      BG011
      value
      24
    units
    Participants
groups
  1. description
    Participants with solid tumors (ST) received carfilzomib (CFZ) 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG000
    title
    P1B ST: CFZ 20 mg/m² Bolus
  2. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG001
    title
    P1B ST: CFZ 20/27 mg/m² Bolus
  3. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG002
    title
    P1B ST: CFZ 20/36 mg/m² Bolus
  4. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG003
    title
    P2 ST: CFZ 20/36 mg/m² Bolus
  5. description
    Participants with solid tumors received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG004
    title
    P1B ST: CFZ 36 mg/m²
  6. description
    Participants with solid tumors received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG005
    title
    P1B ST: CFZ 45 mg/m²
  7. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG006
    title
    P1B ST: CFZ 20/45 mg/m²
  8. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG007
    title
    P1B ST: CFZ 20/56 mg/m²
  9. description
    Participants with solid tumors received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG008
    title
    P1B ST: CFZ 20/70 mg/m²
  10. description
    Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG009
    title
    P1B MM: CFZ 20/36 mg/m²
  11. description
    Participants with multiple myeloma (MM) received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG010
    title
    P1B MM: CFZ 20/45 mg/m²
  12. description
    Participants with multiple myeloma received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
    id
    BG011
    title
    P1b MM: CFZ 20/56 mg/m²
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          14.74
          value
          47.3
        2. group Id
          BG001
          spread
          8.81
          value
          60.8
        3. group Id
          BG002
          spread
          11.72
          value
          60.0
        4. group Id
          BG003
          spread
          9.97
          value
          62.0
        5. comment
          Not applicable for infusion arms
          group Id
          BG004
          spread
          NA
          value
          NA
        6. comment
          Not applicable for infusion arms
          group Id
          BG005
          spread
          NA
          value
          NA
        7. comment
          Not applicable for infusion arms
          group Id
          BG006
          spread
          NA
          value
          NA
        8. comment
          Not applicable for infusion arms
          group Id
          BG007
          spread
          NA
          value
          NA
        9. comment
          Not applicable for infusion arms
          group Id
          BG008
          spread
          NA
          value
          NA
        10. comment
          Not applicable for infusion arms
          group Id
          BG009
          spread
          NA
          value
          NA
        11. comment
          Not applicable for infusion arms
          group Id
          BG010
          spread
          NA
          value
          NA
        12. comment
          Not applicable for infusion arms
          group Id
          BG011
          spread
          NA
          value
          NA
      title
      Bolus Groups
    2. categories
      1. measurements
        1. comment
          Not applicable for bolus arms
          group Id
          BG000
          spread
          NA
          value
          NA
        2. comment
          Not applicable for bolus arms
          group Id
          BG001
          spread
          NA
          value
          NA
        3. comment
          Not applicable for bolus arms
          group Id
          BG002
          spread
          NA
          value
          NA
        4. comment
          Not applicable for bolus arms
          group Id
          BG003
          spread
          NA
          value
          NA
        5. group Id
          BG004
          spread
          5.18
          value
          60.0
        6. group Id
          BG005
          spread
          11.10
          value
          69.9
        7. group Id
          BG006
          spread
          10.38
          value
          61.2
        8. group Id
          BG007
          spread
          7.40
          value
          61.4
        9. group Id
          BG008
          spread
          11.58
          value
          61.6
        10. group Id
          BG009
          spread
          3.77
          value
          63.3
        11. group Id
          BG010
          spread
          5.57
          value
          72.0
        12. group Id
          BG011
          spread
          9.88
          value
          62.7
      title
      30-minute Infusion Groups
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          1
        3. group Id
          BG002
          value
          4
        4. group Id
          BG003
          value
          38
        5. group Id
          BG004
          value
          0
        6. group Id
          BG005
          value
          4
        7. group Id
          BG006
          value
          3
        8. group Id
          BG007
          value
          5
        9. group Id
          BG008
          value
          4
        10. group Id
          BG009
          value
          2
        11. group Id
          BG010
          value
          1
        12. group Id
          BG011
          value
          7
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          3
        4. group Id
          BG003
          value
          27
        5. group Id
          BG004
          value
          6
        6. group Id
          BG005
          value
          3
        7. group Id
          BG006
          value
          3
        8. group Id
          BG007
          value
          5
        9. group Id
          BG008
          value
          7
        10. group Id
          BG009
          value
          2
        11. group Id
          BG010
          value
          2
        12. group Id
          BG011
          value
          17
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        2. group Id
          BG001
          value
          3
        3. group Id
          BG002
          value
          4
        4. group Id
          BG003
          value
          27
        5. group Id
          BG004
          value
          2
        6. group Id
          BG005
          value
          1
        7. group Id
          BG006
          value
          0
        8. group Id
          BG007
          value
          2
        9. group Id
          BG008
          value
          4
        10. group Id
          BG009
          value
          4
        11. group Id
          BG010
          value
          0
        12. group Id
          BG011
          value
          8
      title
      0
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          2
        2. group Id
          BG001
          value
          1
        3. group Id
          BG002
          value
          3
        4. group Id
          BG003
          value
          35
        5. group Id
          BG004
          value
          4
        6. group Id
          BG005
          value
          4
        7. group Id
          BG006
          value
          6
        8. group Id
          BG007
          value
          7
        9. group Id
          BG008
          value
          7
        10. group Id
          BG009
          value
          0
        11. group Id
          BG010
          value
          2
        12. group Id
          BG011
          value
          15
      title
      1
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        4. group Id
          BG003
          value
          0
        5. group Id
          BG004
          value
          0
        6. group Id
          BG005
          value
          2
        7. group Id
          BG006
          value
          0
        8. group Id
          BG007
          value
          1
        9. group Id
          BG008
          value
          0
        10. group Id
          BG009
          value
          0
        11. group Id
          BG010
          value
          1
        12. group Id
          BG011
          value
          1
      title
      2
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        2. group Id
          BG001
          value
          0
        3. group Id
          BG002
          value
          0
        4. group Id
          BG003
          value
          3
        5. group Id
          BG004
          value
          0
        6. group Id
          BG005
          value
          0
        7. group Id
          BG006
          value
          0
        8. group Id
          BG007
          value
          0
        9. group Id
          BG008
          value
          0
        10. group Id
          BG009
          value
          0
        11. group Id
          BG010
          value
          0
        12. group Id
          BG011
          value
          0
      title
      Missing
    description
    Scale used to assess how a patient's disease is progressing, how the disease affects the daily living abilities of the patient: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about \> 50% of waking hours; 3 = Capable of only limited self care, confined to a bed or chair \> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.
    param Type
    NUMBER
    title
    Eastern Cooperative Oncology Group (ECOG) Performance Status
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice